SAN DIEGO, January 12, 2021 – Today, Primmune Therapeutics announced the close of its Series A financing round with the addition of $4.0 million from Bioqube Ventures, a European life sciences venture capital firm. This brings the total of the Series A financing raise to $31.4 million. These funds will be used to support the development of PRTX007, a novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonist as a therapeutic-adjuvant for acute viral diseases and cancer.

Concurrently, Debbie Dumont, Co-founder and Managing Partner at Bioqube Ventures has joined Primmune’s Board of Directors as an observer. Elina Zuniga, Ph.D., Professor of Molecular Biology at the University of California, San Diego has joined the company’s scientific advisory board.

“We are excited to have Bioqube Ventures join our investor syndicate because of their expertise and experience in establishing European operations. Bioqube Ventures will facilitate the establishment of our Belgium subsidiary to complement our Australian presence and enable us to effectively partner and run clinical studies in the European Union as well as in the United States and Australia,” said Charlie McDermott, Chairman and Chief Executive Officer of Primmune Therapeutics. “Dr. Elina Zuniga will be important in guiding our TLR7 agonist strategy as part of our scientific advisory board given her deep knowledge regarding the interplay between toll-like receptor signaling, endogenous poly-interferon antiviral responses, and host innate immune modulation.”

About Primmune Therapeutics

Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases. For more information, please visit: www.primmunerx.com.

Media Contact:

Cammy Duong
Westwicke, an ICR company
Cammy.Duong@westwicke.com
203-682-8380